To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Zyprexa Cleared for Marketing in European Union for Schizophrenia URL: http://www.pslgroup.com/dg/CAC2.htm Doctor's Guide September 27, 1996
INDIANAPOLIS, Sept. 27, 1996-- Eli Lilly and Company announced today that it has received approval through the European Medicine Evaluation Agency (EMEA) in Europe to market Zyprexa(TM) in 15 European Union member countries for the treatment of schizophrenia, the long-term maintenance treatment of schizophrenia and the treatment of co-morbid depression, or depression that may occur with schizophrenia. Schizophrenia is one of the most chronic and debilitating of the mental illnesses, affecting 1 percent of the world's population. Schizophrenia is marked by the presence of positive symptoms, such as delusions and hallucinations, and negative symptoms, such as diminished emotions and low motivation. Many currently available older antipsychotic medications are perceived as having little or no effect on negative symptoms. These medications also have been linked to extrapyramidal syndrome (EPS) events, including abnormal muscle spasms, Parkinson's disease-like symptoms, abnormal jerking or writhing, and an inability to sit still. The Committee for Proprietary Medicinal Products (CPMP) cleared Zyprexa for marketing after evaluating the results of Lilly's data from more than 3,100 individuals in 22 countries, with more than 200 clinical investigators conducting the studies. Zyprexa is currently under review by the U.S. Food and Drug Administration and has not been approved for marketing anywhere outside Europe. Eli Lilly and Company is a global, research-based pharmaceutical corporation headquartered in Indianapolis, Ind., that is dedicated to creating and delivering superior health care solutions -- by combining pharmaceutical innovation, existing pharmaceutical technology, disease prevention and management and information technologies -- in order to provide customers worldwide with optimal clinical and economic outcomes. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.